Fog City Capital

Fctry lab combine traditional manufacturing methods with modern technology, allowing us to redefine techniques and invent new construction methods

Fctry lab combine traditional manufacturing methods with modern technology, allowing us to redefine techniques and invent new construction methods

Ad-Lib.io is a UK-based digital creative technology and service company specializing in the production and activation of creative assets for digital advertising. As a Double Click Creative Marketing Partner, it collaborates with platforms like Facebook and DoubleClick to enhance the deployment of optimized digital creative. Ad-Lib.io's AI-driven platform streamlines digital ad workflows, automating standard processes to significantly reduce campaign build times. The company offers features such as dynamic video capabilities, A/B testing, and a full preview solution, all designed to improve creative effectiveness. By focusing solely on delivering high-quality creative rather than media buying, Ad-Lib.io aims to achieve time savings of up to 46% and performance uplifts of up to 80% for its clients.

Ad-Lib.io is a UK-based digital creative technology and service company specializing in the production and activation of creative assets for digital advertising. As a Double Click Creative Marketing Partner, it collaborates with platforms like Facebook and DoubleClick to enhance the deployment of optimized digital creative. Ad-Lib.io's AI-driven platform streamlines digital ad workflows, automating standard processes to significantly reduce campaign build times. The company offers features such as dynamic video capabilities, A/B testing, and a full preview solution, all designed to improve creative effectiveness. By focusing solely on delivering high-quality creative rather than media buying, Ad-Lib.io aims to achieve time savings of up to 46% and performance uplifts of up to 80% for its clients.

Visual IQ is a leading provider of cross-channel marketing attribution software, established in 2006. The company offers its SaaS-based IQ Intelligence Suite, which delivers in-depth insights into cross-channel marketing performance by analyzing complex data sets. This platform provides actionable recommendations and optimized media plans that enhance the effectiveness of marketing strategies across both online and offline channels, thereby increasing return on investment. Visual IQ utilizes advanced multi-dimensional fractional attribution science and predictive analytics to help marketers identify and capitalize on improvement opportunities. The company's contributions to the field have been recognized through various awards, including The Drum's Digital Trading Award for Best Attribution Solution and the ASPY Award for Best Data or Analytics Solution. Visual IQ is also actively involved in industry organizations, serving on councils and committees related to advertising technology and data analytics.

Cianna Medical, Inc. is a women's health company focused on developing innovative medical technologies for the treatment of early-stage breast cancer. Headquartered in Aliso Viejo, California, the company was incorporated in 2007 and is dedicated to enhancing breast conservation therapy (BCT) options for women diagnosed with breast cancer. Cianna Medical's notable products include SAVI SCOUT, a wire-free radar localization solution that assists in accurately locating breast tumors, and SAVI Brachy, which delivers targeted radiation to minimize damage to surrounding healthy tissue. Additionally, the company provides a surgical guidance system that utilizes real-time audible and visual indicators to improve precision during lumpectomy and excisional biopsy procedures. Through its advancements, Cianna Medical aims to increase access to effective treatment options for women facing breast cancer. As of November 2018, Cianna Medical operates as a subsidiary of Merit Medical Systems, Inc.

Visual IQ is a leading provider of cross-channel marketing attribution software, established in 2006. The company offers its SaaS-based IQ Intelligence Suite, which delivers in-depth insights into cross-channel marketing performance by analyzing complex data sets. This platform provides actionable recommendations and optimized media plans that enhance the effectiveness of marketing strategies across both online and offline channels, thereby increasing return on investment. Visual IQ utilizes advanced multi-dimensional fractional attribution science and predictive analytics to help marketers identify and capitalize on improvement opportunities. The company's contributions to the field have been recognized through various awards, including The Drum's Digital Trading Award for Best Attribution Solution and the ASPY Award for Best Data or Analytics Solution. Visual IQ is also actively involved in industry organizations, serving on councils and committees related to advertising technology and data analytics.

Cianna Medical, Inc. is a women's health company focused on developing innovative medical technologies for the treatment of early-stage breast cancer. Headquartered in Aliso Viejo, California, the company was incorporated in 2007 and is dedicated to enhancing breast conservation therapy (BCT) options for women diagnosed with breast cancer. Cianna Medical's notable products include SAVI SCOUT, a wire-free radar localization solution that assists in accurately locating breast tumors, and SAVI Brachy, which delivers targeted radiation to minimize damage to surrounding healthy tissue. Additionally, the company provides a surgical guidance system that utilizes real-time audible and visual indicators to improve precision during lumpectomy and excisional biopsy procedures. Through its advancements, Cianna Medical aims to increase access to effective treatment options for women facing breast cancer. As of November 2018, Cianna Medical operates as a subsidiary of Merit Medical Systems, Inc.

Proprius Pharmaceuticals is a San Diego-based drug developer focused on rheumatology and autoimmune diseases. The company offers two early clinical-stage therapeutic candidates comprising a product to treat pain and a product to treat rheumatoid arthritis. Proprius Pharmaceuticals was founded in 2005.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary prescription therapeutics for significant medical conditions with unmet needs and high levels of patient dissatisfaction. The company primarily targets diseases and disorders in the central nervous system therapeutic area. Currently, Somaxon promotes Silenor, the first and only nonscheduled prescription medication approved in the United States for the treatment of sleep maintenance insomnia. In addition to its focus on insomnia, Somaxon has been involved in developing products for other conditions, including middle ear infections, head lice, and cough and cold. The company's efforts are directed toward in-licensing, developing, and marketing both proprietary products and late-stage candidates to address various health challenges.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.

DexCom is a company that develops advanced glucose sensing technologies, primarily focusing on continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1999, the company builds on research from 1967 at the University of Wisconsin regarding implanted glucose sensors. DexCom's CGM systems offer a modern alternative to traditional blood glucose meters, enabling real-time monitoring of glucose levels. The company is also enhancing its systems to integrate with insulin pumps, facilitating automatic insulin delivery. This innovation aims to improve the management of diabetes and enhance the quality of life for patients.

Guava Technologies, Inc. is a biotechnology and medical device manufacturer based in Hayward, California. Founded in 1998, the company specializes in the development, design, and manufacturing of products used primarily in cell biology research and clinical diagnostics. Its offerings include a range of assays for monitoring HIV/AIDS, cell counting, antibody quantification, cytotoxicity, and apoptosis, as well as benchtop cell analysis systems. Guava Technologies also produces flow cytometry systems tailored for various applications in life science research and drug discovery. As of 2009, Guava Technologies operates as a subsidiary of Millipore Corp.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.